Integrated DNA Technologi?es Enhances its qPCR Probe Portfolio
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has further expanded its portfolio of PrimeTime® qPCR products with the launch of two new probes. The PrimeTime Eco Probe and PrimeTime Mini LNA Probe complete the existing offering, providing new options for customers performing gene expression and genotyping experiments.
Developed to support customers looking for a cost-effective option at the mid-scale range, the Eco Probe is delivered at a normalised yield of 2.5 nmoles, sufficient for approximately 500 reactions, bridging the space between the existing PrimeTime Mini qPCR Probe (0.5 nmole normalized yield, 100 reactions) and the 100 nmole synthesis scale (minimum guaranteed yield of 10 nmoles). If ordered with the option of an internal ZEN quencher, the double-quenched PrimeTime Eco Probe will generate less background noise, while increasing end point signal, to significantly boost qPCR sensitivity and precision when compared to traditional single-quenched probes. The Eco Probe is available with a FAM/ZEN/IA Black FQ dye/quencher combination.
When genotyping via PCR, it is often useful to be able to perform a few reactions using a small subset of probes, in order to test and consequently optimise LNA probe design. The new PrimeTime Mini LNA Probes enable customers to do as few as 100 reactions, allowing preliminary experiments to be performed at a low initial cost.
Guidelines for LNA probe design are available online, under the Overview tab to aid users in their initial design. IDT can also provide full design support, if required — design fees may apply. The Mini LNA Probes join the existing 250 nmole PrimeTime LNA Probes, which provide 8000 reactions and are ideal for large-scale screening.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...